JP2017506627A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506627A5
JP2017506627A5 JP2016550664A JP2016550664A JP2017506627A5 JP 2017506627 A5 JP2017506627 A5 JP 2017506627A5 JP 2016550664 A JP2016550664 A JP 2016550664A JP 2016550664 A JP2016550664 A JP 2016550664A JP 2017506627 A5 JP2017506627 A5 JP 2017506627A5
Authority
JP
Japan
Prior art keywords
medicament
salt
medicament according
agent
carbamimidoamidobenzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016550664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506627A (ja
JP6383427B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/000639 external-priority patent/WO2015122187A1/en
Publication of JP2017506627A publication Critical patent/JP2017506627A/ja
Publication of JP2017506627A5 publication Critical patent/JP2017506627A5/ja
Application granted granted Critical
Publication of JP6383427B2 publication Critical patent/JP6383427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016550664A 2014-02-13 2015-02-12 縮合複素環化合物 Active JP6383427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014025832 2014-02-13
JP2014025832 2014-02-13
PCT/JP2015/000639 WO2015122187A1 (en) 2014-02-13 2015-02-12 Fused heterocyclic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018146459A Division JP6529649B2 (ja) 2014-02-13 2018-08-03 縮合複素環化合物

Publications (3)

Publication Number Publication Date
JP2017506627A JP2017506627A (ja) 2017-03-09
JP2017506627A5 true JP2017506627A5 (enExample) 2018-03-08
JP6383427B2 JP6383427B2 (ja) 2018-08-29

Family

ID=52589729

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016550664A Active JP6383427B2 (ja) 2014-02-13 2015-02-12 縮合複素環化合物
JP2018146459A Active JP6529649B2 (ja) 2014-02-13 2018-08-03 縮合複素環化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018146459A Active JP6529649B2 (ja) 2014-02-13 2018-08-03 縮合複素環化合物

Country Status (41)

Country Link
US (2) US9346776B2 (enExample)
EP (1) EP3105213B1 (enExample)
JP (2) JP6383427B2 (enExample)
KR (1) KR102378454B1 (enExample)
CN (1) CN105980370B (enExample)
AR (1) AR099400A1 (enExample)
AU (1) AU2015216438B2 (enExample)
BR (1) BR112016018455B1 (enExample)
CA (1) CA2938191C (enExample)
CL (1) CL2016001911A1 (enExample)
CR (1) CR20160367A (enExample)
CY (1) CY1121534T1 (enExample)
DK (1) DK3105213T3 (enExample)
DO (1) DOP2016000206A (enExample)
EA (1) EA032201B1 (enExample)
EC (1) ECSP16067137A (enExample)
ES (1) ES2717113T3 (enExample)
GE (1) GEP20176808B (enExample)
HR (1) HRP20190369T1 (enExample)
HU (1) HUE042709T2 (enExample)
IL (1) IL246838B (enExample)
JO (1) JO3472B1 (enExample)
LT (1) LT3105213T (enExample)
MA (1) MA39246A1 (enExample)
ME (1) ME03422B (enExample)
MX (1) MX368392B (enExample)
MY (1) MY173607A (enExample)
NZ (1) NZ722035A (enExample)
PE (1) PE20161243A1 (enExample)
PH (1) PH12016501582B1 (enExample)
PL (1) PL3105213T3 (enExample)
PT (1) PT3105213T (enExample)
RS (1) RS58498B1 (enExample)
SG (1) SG11201605654QA (enExample)
SI (1) SI3105213T1 (enExample)
SM (1) SMT201900175T1 (enExample)
TR (1) TR201903892T4 (enExample)
TW (1) TWI669297B (enExample)
UA (1) UA118280C2 (enExample)
UY (1) UY35994A (enExample)
WO (1) WO2015122187A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022762B1 (pt) * 2013-03-13 2022-08-16 Takeda Pharmaceutical Company Limited Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
JP6634070B2 (ja) * 2015-03-27 2020-01-22 武田薬品工業株式会社 縮合複素環化合物
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
JPWO2019088270A1 (ja) * 2017-11-02 2020-12-03 宇部興産株式会社 蛋白分解酵素の双頭型阻害剤
SG11202011083PA (en) * 2018-05-09 2020-12-30 Lg Chemical Ltd Novel compound exhibiting enteropeptidase inhibitory activity
EP3650440A4 (en) 2018-08-27 2020-11-25 Scohia Pharma, Inc. BENZOIC ESTER COMPOUND
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US20220281866A1 (en) 2019-07-19 2022-09-08 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
WO2021166899A1 (ja) * 2020-02-17 2021-08-26 宇部興産株式会社 インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
CN111544599B (zh) * 2020-07-10 2020-12-01 有术肌肤管理(深圳)有限公司 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
TW202539626A (zh) * 2023-12-01 2025-10-16 日商Ea製藥股份有限公司 醫藥組成物
TW202532060A (zh) * 2023-12-01 2025-08-16 日商Ea製藥股份有限公司 醫藥組成物
WO2025211248A1 (ja) * 2024-04-04 2025-10-09 Eaファーマ株式会社 医薬組成物
WO2026063442A1 (ja) * 2024-09-18 2026-03-26 Eaファーマ株式会社 医薬組成物

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd 4―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
EP0673924A4 (en) 1992-12-10 1996-04-24 Teikoku Chem Ind Co Ltd PROPRIONIC ACID DERIVATIVE.
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
JPH09124571A (ja) 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
EP0893437A4 (en) 1996-04-10 2000-12-27 Ono Pharmaceutical Co GUANIDINO TRYPTASE INHIBITOR
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターd阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規4h−3,1−ベンゾオキサジン−4−オン誘導体
JPH10306025A (ja) 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7671057B2 (en) 2004-11-08 2010-03-02 Ono Pharmaceutical Co., Ltd. Therapeutic agent for type II diabetes comprising protease-inhibiting compound
CA2588087A1 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
EP1811865B1 (en) 2004-11-26 2008-07-16 N.V. Nutricia Infant nutrition with protease inhibitor
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JP2006348023A (ja) * 2005-05-17 2006-12-28 Santen Pharmaceut Co Ltd アミン誘導体を有効成分として含む血管新生阻害剤
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007208495A1 (en) * 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2225261B1 (en) 2007-12-03 2016-03-09 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
CN102822154B (zh) 2009-12-07 2016-06-01 味之素株式会社 杂芳基羧酸酯衍生物
WO2012169579A1 (ja) 2011-06-07 2012-12-13 味の素株式会社 ヘテロ環カルボン酸エステル誘導体
JP6048409B2 (ja) 2011-09-15 2016-12-21 アステラス製薬株式会社 グアニジノ安息香酸化合物
WO2013102899A1 (en) 2012-01-03 2013-07-11 Oramed Ltd. Methods and compositions for treating diabetes
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
EP2964644B1 (en) 2013-03-08 2018-12-26 Amgen, Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
BR112015022762B1 (pt) 2013-03-13 2022-08-16 Takeda Pharmaceutical Company Limited Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai

Similar Documents

Publication Publication Date Title
JP2015513557A5 (enExample)
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
IL250239A0 (en) Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
EA201691624A1 (ru) Гетероциклическое соединение
BR112015021027A2 (pt) compostos terapêuticos
DK3292116T3 (da) 3-aryl-4-amido-bicykliske [4,5,0]hydroxamsyrer som hdac-inhibitorer
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
CL2014003168A1 (es) Compuestos derivados de tetrahidrofurano o tetrahidrotiofeno teniendo un resto d-aminoacido; composicion farmaceutica que los comprende, util para el tratamiento de un huesped infectado con el virus de la hepatitis c.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
JO3472B1 (ar) مركبات ديهايدروبنزوفوران مفيدة في علاج السكري والسمنة
EA201591397A1 (ru) Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса
MX375068B (es) Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
HUE057063T2 (hu) Topikális gyógyászati készítmény, amely legalább amitriptilint tartalmaz, perifériás neuropátiás fájdalom kezelésére
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
MX387796B (es) Compuestos de aminocarbonilcarbamato.
MX374245B (es) Derivados de naftiridinadiona.
PH12015502023B1 (en) Guanidinobenzoic acid ester compound
FI3878444T3 (fi) (n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena
JP2018150270A5 (enExample)